Ebun Garner
Net worth: 459 392 $ as of 30/06/2026
Net worth: 459 392 $ as of 30/06/2026
Ebun S.
Garner currently works at Erasca, Inc., as Secretary & General Counsel from 2021.
Mr. Garner also formerly worked at Scient'x SA, as Director General, Neurocrine Biosciences, Inc., as Associate General Counsel from 2017 to 2019, ACADIA Pharmaceuticals, Inc., as Assistant General Counsel from 2020 to 2021, Alphatec Holdings, Inc., as Secretary, Senior Vice President & General Counsel from 2011 to 2017, Mintz, Levin, Cohn, Ferris, Glovsky & Popeo PC, as Associate from 2000 to 2005, Squadron, Ellenoff, Plesent & Sheinfeld LLP, as Associate from 1999 to 2000, Alphatec Spine, Inc., as Secretary, Senior Vice President & General Counsel from 2011 to 2017, and Imbria Pharmaceuticals, Inc., as Secretary & Chief Legal Officer from 2019 to 2020.
Mr. Garner received his undergraduate degree from the University of Pennsylvania and graduate degree from New York University School of Law.
| Company | Date | Number of shares | Valuation | Valuation date |
|---|---|---|---|---|
ERASCA, INC. 0.01% | 01/04/2026 | 25,076 ( 0.01% ) | 459 392 $ | 30/06/2026 |
| Companies | Position | Start |
|---|---|---|
| ERASCA, INC. | General Counsel | 01/04/2021 |
| Companies | Position | End |
|---|---|---|
| ACADIA PHARMACEUTICALS INC. | Corporate Officer/Principal | 01/04/2021 |
Imbria Pharmaceuticals, Inc.
Imbria Pharmaceuticals, Inc. Miscellaneous Commercial ServicesCommercial Services Operates as a clinical stage company for the treatment of cardiovascular disease | General Counsel | 01/07/2020 |
| NEUROCRINE BIOSCIENCES, INC. | Corporate Officer/Principal | 01/04/2019 |
| ALPHATEC HOLDINGS, INC. | Investor Relations Contact | 23/07/2012 |
Alphatec Spine, Inc.
Alphatec Spine, Inc. Medical SpecialtiesHealth Technology Designs, manufactures, and sells medical devices for surgical treatment of spine disorders | General Counsel | 28/02/2017 |
Active
Inactive
Listed companies
Private companies
1st degree connections
1st degree companies
Male
Female
Members of the board
Executives
| Private companies | 11 |
|---|---|
Neurocrine Biosciences, Inc.
Neurocrine Biosciences, Inc. BiotechnologyHealth Technology Discovers, develops and commercializes treatments for neurological, neuroendocrine and neuropsychiatric disorders | Health Technology |
ACADIA Pharmaceuticals, Inc.
ACADIA Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Develops pharmaceuticals drugs for treatment of central nervous system disorders | Health Technology |
Alphatec Holdings, Inc.
Alphatec Holdings, Inc. Medical SpecialtiesHealth Technology Operates as a holding company with interests in medical equipment and supplies | Health Technology |
Mintz, Levin, Cohn, Ferris, Glovsky & Popeo PC
Mintz, Levin, Cohn, Ferris, Glovsky & Popeo PC Miscellaneous Commercial ServicesCommercial Services Provides legal services | Commercial Services |
University of Pennsylvania
University of Pennsylvania Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Squadron, Ellenoff, Plesent & Sheinfeld LLP
Squadron, Ellenoff, Plesent & Sheinfeld LLP Miscellaneous Commercial ServicesCommercial Services Provides legal services | Commercial Services |
Scient'x SA
Scient'x SA Medical SpecialtiesHealth Technology Designs, develops and markets spinal implant devices for the lumbar, thoracic and cervical spine | Health Technology |
Alphatec Spine, Inc.
Alphatec Spine, Inc. Medical SpecialtiesHealth Technology Designs, manufactures, and sells medical devices for surgical treatment of spine disorders | Health Technology |
New York University School of Law
New York University School of Law Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Imbria Pharmaceuticals, Inc.
Imbria Pharmaceuticals, Inc. Miscellaneous Commercial ServicesCommercial Services Operates as a clinical stage company for the treatment of cardiovascular disease | Commercial Services |
Erasca, Inc.
Erasca, Inc. Pharmaceuticals: MajorHealth Technology Develops, discovers and commercializes therapies for RAS/MAPK pathway-driven cancers | Health Technology |
Select your edition
All financial news and data tailored to specific country editions